FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Clinical trials for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine targets rare liver cancer's genetic Achilles' heel
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized peptide vaccine for people with fibrolamellar hepatocellular carcinoma (a rare liver cancer) or other tumors that share a specific genetic mutation called DNAJB1-PRKACA. The vaccine is designed to teach the body's immune cells to recogn…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: University Hospital Tuebingen • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:49 UTC
-
New vaccine combo targets rare liver cancer in early trial
Disease control Recruiting nowThis study tests a vaccine that targets a specific protein found only in fibrolamellar carcinoma (FLC), a rare liver cancer. The vaccine is given together with two immunotherapy drugs (nivolumab and ipilimumab) to boost the immune system's attack on cancer cells. The trial includ…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 11, 2026 20:53 UTC